Ischemic Memory Imaging in Nonhuman Primates with Echocardiographic Molecular Imaging of Selectin Expression - 19/06/14
, Scott M. Chadderdon, MD, J. Todd Belcik, BS, RCS, RDCS, Saurabh Gupta, MD, Jonathan R. Lindner, MDAbstract |
Background |
Selectins are adhesion molecules that are expressed by the vascular endothelium upon activation and may be an imaging target for detecting myocardial ischemia long after resolution. The aim of this study was to test the hypothesis that molecular imaging of selectins with myocardial contrast echocardiographic (MCE) molecular imaging could be used to detect recent brief ischemia in closed-chest nonhuman primates.
Methods |
Myocardial ischemia was produced in anesthetized adult rhesus macaques (n = 6) by percutaneous balloon catheter occlusion of the left anterior descending or circumflex coronary artery for 5 to 10 min. Three separate macaques served as nonischemic controls. MCE perfusion imaging was performed during coronary occlusion to measure risk area and at 100 to 110 min to exclude infarction. MCE molecular imaging was performed at 30 and 90 min after reperfusion using a lipid microbubble bearing dimeric recombinant human P-selectin glycoprotein ligand–1 (MB-YSPSL). Collection of blood for safety data, electrocardiography, and echocardiography were performed at baseline and before and 10 min after each MB-YSPSL injection.
Results |
Vital signs, oxygen saturation, electrocardiographic results, ventricular systolic function, pulmonary vascular resistance, and serum safety markers were unchanged by intravenous injection of MB-YSPSL. On echocardiography, left ventricular dysfunction in the risk area had resolved by 30 min, and there was no evidence of infarction on MCE perfusion imaging. On selectin-targeted MCE molecular imaging, signal enhancement was greater (P < .05) in the risk area than remote territory at 30 min (25 ± 11 vs 11 ± 4 IU) and 90 min (13 ± 3 vs 3 ± 2 IU) after ischemia. There was no enhancement (<1 IU) in control nonischemic subjects.
Conclusions |
In primates, MCE molecular imaging of selectins using MB-YSPSL, a recombinant ligand appropriate for humans, is both safe and effective for imaging recent myocardial ischemia. This technique may be useful for detecting recent ischemia in patients with chest pain even in the absence of necrosis.
Le texte complet de cet article est disponible en PDF.Keywords : Molecular imaging, Contrast echocardiography, Ischemia, Selectins
Abbreviations : ACS, BP, CO, ECG, HR, LV, MCE, PSGL-1
Plan
| Dr Lindner is supported by grants R01-HL-078610, R01-DK-063508, R01HL111969, and RC1-HL-100659 from the National Institutes of Health (Bethesda, MD), and Dr Davidson is supported by grant T32-HL-094294-01 from the National Institutes of Health. Dr Chadderdon is supported by a Fellow-to-Faculty Transition Award from the American Heart Association (Dallas, TX). |
|
| MB-YSPSL was manufactured and provided for this study by Bracco Imaging SA (Manno, Switzerland). There was no input from Bracco Imaging on study design, data analysis, or report preparation. |
|
| Paul A. Grayburn, MD, served as Guest Editor for this report. |
Vol 27 - N° 7
P. 786 - juillet 2014 Retour au numéro
Article précédent
- Detection of Coronary Artery Disease Using Coronary Flow Velocity Reserve by Transthoracic Doppler Echocardiography versus Multidetector Computed Tomography Coronary Angiography: Influence of Calcium Score
- Kentaro Kakuta, Kaoru Dohi, Tomomi Yamada, Takashi Yamanaka, Masaki Kawamura, Shiro Nakamori, Hiroshi Nakajima, Takashi Tanigawa, Katsuya Onishi, Norikazu Yamada, Mashio Nakamura, Masaaki Ito
- Superior Vena Cava Flow Is a Clinically Valid Measurement in the Preterm Newborn
- Martin R. Kluckow, Nicholas J. Evans
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?